Clinical Site Partners — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$282,843	37
2024	Research	$117,753	39
2023	Research	$3,834,775	639
2022	Research	$3,113,636	802
2021	Research	$2,923,161	235
2020	Research	$537	2

Breakdown

Who paid Research payments · program years 2020–2025

Regeneron Pharmaceuticals, Inc. $6,184,615 1,128 payments
Bavarian Nordic A/S $3,606,234 536 payments
Moderna TX, Inc. $282,121 35 payments
Pfizer Inc. $161,583 43 payments
Roche Products Limited $25,935 6 payments
F. Hoffmann-La Roche AG $12,218 6 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers $3,858,073 581 payments
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $3,588,200 524 payments
A Phase 1, Randomized, Open-Label Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers $1,013,088 486 payments
A Phase 2 Study to Assess the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Outpatients With SARS-CoV-2 Infection $876,146 18 payments
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $272,321 30 payments
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $195,586 23 payments
A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe Disease $150,750 2 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 $90,972 18 payments
A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $70,268 16 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2 Arm Study to Investigate Orally Administered PF 07321332Ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Low Risk of Progressing to Severe Illness $62,089 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.